AIMS/HYPOTHESIS: Genetic variants of upstream transcription factor 1 (USF1) have previously been associated with dyslipidaemias in family studies. Our aim was to further address the role of USF1 in metabolic syndrome and cardiovascular traits at the population level in a large Swedish male cohort (n=2,322) with multiple measurements for risk factors during 32 years of follow-up. METHODS: Participants, born in 1920-1924, were examined at 50, 60, 70 and 77 years of age. The follow-up period for cardiovascular events was 1970-2002. We genotyped three haplotype tagging polymorphisms capturing the major allelic variants of USF1. RESULTS: SNP rs2774279 was associated with the metabolic syndrome. The minor allele of rs2774279 was less common among individuals with metabolic syndrome than among healthy controls [p=0.0029 when metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III; p=0.0073 when defined according to the International Diabetes Federation (IDF)]. The minor allele of rs2774279 was also associated with lower BMI, lower fasting glucose values and higher HDL-cholesterol concentrations in longitudinal analyses. With SNP rs2073658, a borderline association with metabolic syndrome was observed (p=0.036, IDF), the minor allele being the risk-increasing allele. The minor allele of rs2073658 also associated with higher total and LDL-cholesterol, apolipoprotein B-100 and lipoprotein(a) concentrations in longitudinal analyses. Importantly, these trends with respect to the allelic variants prevailed throughout the follow-up time of three decades. CONCLUSIONS/ INTERPRETATION: Our results suggest that USF1 variants associate with the metabolic syndrome at population level and influence the cardiovascular risk factors throughout adulthood in a consistent, longitudinal manner.
AIMS/HYPOTHESIS: Genetic variants of upstream transcription factor 1 (USF1) have previously been associated with dyslipidaemias in family studies. Our aim was to further address the role of USF1 in metabolic syndrome and cardiovascular traits at the population level in a large Swedish male cohort (n=2,322) with multiple measurements for risk factors during 32 years of follow-up. METHODS:Participants, born in 1920-1924, were examined at 50, 60, 70 and 77 years of age. The follow-up period for cardiovascular events was 1970-2002. We genotyped three haplotype tagging polymorphisms capturing the major allelic variants of USF1. RESULTS: SNP rs2774279 was associated with the metabolic syndrome. The minor allele of rs2774279 was less common among individuals with metabolic syndrome than among healthy controls [p=0.0029 when metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III; p=0.0073 when defined according to the International Diabetes Federation (IDF)]. The minor allele of rs2774279 was also associated with lower BMI, lower fasting glucose values and higher HDL-cholesterol concentrations in longitudinal analyses. With SNP rs2073658, a borderline association with metabolic syndrome was observed (p=0.036, IDF), the minor allele being the risk-increasing allele. The minor allele of rs2073658 also associated with higher total and LDL-cholesterol, apolipoprotein B-100 and lipoprotein(a) concentrations in longitudinal analyses. Importantly, these trends with respect to the allelic variants prevailed throughout the follow-up time of three decades. CONCLUSIONS/ INTERPRETATION: Our results suggest that USF1 variants associate with the metabolic syndrome at population level and influence the cardiovascular risk factors throughout adulthood in a consistent, longitudinal manner.
Authors: M C Y Ng; K Miyake; W Y So; E W M Poon; V K L Lam; J K Y Li; N J Cox; G I Bell; J C N Chan Journal: Diabetologia Date: 2005-08-26 Impact factor: 10.122
Authors: Eleftheria Zeggini; Coleen M Damcott; Robert L Hanson; Mohammad A Karim; N William Rayner; Christopher J Groves; Leslie J Baier; Terri C Hale; Andrew T Hattersley; Graham A Hitman; Sarah E Hunt; William C Knowler; Braxton D Mitchell; Maggie C Y Ng; Jeffrey R O'Connell; Toni I Pollin; Martine Vaxillaire; Mark Walker; Xiaoqin Wang; Pamela Whittaker; Kunsan Xiang; Xiang Kunsun; Weiping Jia; Juliana C N Chan; Philippe Froguel; Panos Deloukas; Alan R Shuldiner; Steven C Elbein; Mark I McCarthy Journal: Diabetes Date: 2006-09 Impact factor: 9.461
Authors: Sulin Wu; Rebecca Mar-Heyming; Eric Z Dugum; Nicholas A Kolaitis; Hongxiu Qi; Päivi Pajukanta; Lawrence W Castellani; Aldons J Lusis; Thomas A Drake Journal: Hum Mol Genet Date: 2009-12-08 Impact factor: 6.150
Authors: R J Webster; N M Warrington; M N Weedon; A T Hattersley; P A McCaskie; J P Beilby; L J Palmer; T M Frayling Journal: Diabetologia Date: 2008-11-19 Impact factor: 10.122
Authors: Pirkka-Pekka Laurila; Jussi Naukkarinen; Kati Kristiansson; Samuli Ripatti; Tuuli Kauttu; Kaisa Silander; Veikko Salomaa; Markus Perola; Pekka J Karhunen; Philip J Barter; Christian Ehnholm; Leena Peltonen Journal: Arterioscler Thromb Vasc Biol Date: 2009-11-12 Impact factor: 8.311
Authors: Yue-Mei Fan; Jussi Hernesniemi; Niku Oksala; Mari Levula; Emma Raitoharju; Auni Collings; Nina Hutri-Kähönen; Markus Juonala; Jukka Marniemi; Leo-Pekka Lyytikäinen; Ilkka Seppälä; Ari Mennander; Matti Tarkka; Antti J Kangas; Pasi Soininen; Juha Pekka Salenius; Norman Klopp; Thomas Illig; Tomi Laitinen; Mika Ala-Korpela; Reijo Laaksonen; Jorma Viikari; Mika Kähönen; Olli T Raitakari; Terho Lehtimäki Journal: Sci Rep Date: 2014-04-11 Impact factor: 4.379
Authors: Maria Lytrivi; Kassem Ghaddar; Miguel Lopes; Victoria Rosengren; Anthony Piron; Xiaoyan Yi; Henrik Johansson; Janne Lehtiö; Mariana Igoillo-Esteve; Daniel A Cunha; Lorella Marselli; Piero Marchetti; Henrik Ortsäter; Decio L Eizirik; Miriam Cnop Journal: BMC Genomics Date: 2020-08-26 Impact factor: 3.969